Us Bancorp \De\ Cytom X Therapeutics, Inc. Transaction History
Us Bancorp \De\
- $75.6 Billion
- Q4 2024
A detailed history of Us Bancorp \De\ transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 30,792 shares of CTMX stock, worth $25,249. This represents 0.0% of its overall portfolio holdings.
Number of Shares
30,792
Previous 33,792
8.88%
Holding current value
$25,249
Previous $39,000
20.51%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding CTMX
# of Institutions
71Shares Held
46.1MCall Options Held
3.7KPut Options Held
4.7K-
Tang Capital Management LLC San Diego, CA7.31MShares$6 Million0.57% of portfolio
-
Bvf Inc San Francisco, CA5.23MShares$4.29 Million0.2% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.16MShares$4.23 Million0.0% of portfolio
-
Prosight Management, LP Dallas, TX3.91MShares$3.2 Million1.19% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.22MShares$2.64 Million0.0% of portfolio
About CytomX Therapeutics, Inc.
- Ticker CTMX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,950,200
- Market Cap $54.1M
- Description
- CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...